Pelthos Therapeutics Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures
Pelthos Therapeutics Inc. (PTHS) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures of 0 shares for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-13.
Financial Statements › Shareholders' Equity › Shares Granted or Issued, Share-Based Payment Arrangement › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod · last filed 2025-05-13
- Pelthos Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2025-03-31 was 0.00 shares.
- Pelthos Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2024-12-31 was 50.00K shares.
- Pelthos Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2024-09-30 was 0.00 shares.
- Pelthos Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2024-06-30 was 634.00K shares, a 1119.21% increase year-over-year.
- Pelthos Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2024 was 684.00K shares, a 331.08% increase from fiscal 2023.
- Pelthos Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2023 was 158.67K shares.
- Pelthos Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2022 was 0.00 shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 12 month as first filed |
|---|---|---|---|---|---|
| 2025-03-31 | 0.00 shares 10-Q · filed 2025-05-13 | 50.00K shares derived: sum of 2 quarters · filed 2025-05-13 | 50.00K shares derived: sum of 3 quarters · filed 2025-05-13 | 684.00K shares derived: sum of 4 quarters · filed 2025-05-13 | |
| 2024-12-31 | 50.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | 50.00K shares derived: sum of 2 quarters · filed 2025-03-27 | 684.00K shares derived: sum of 3 quarters · filed 2025-03-27 | 684.00K shares 10-K · filed 2025-03-27 | |
| 2024-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | 634.00K shares derived: sum of 2 quarters · filed 2024-11-13 | 634.00K shares 10-Q · filed 2024-11-13 | 634.00K shares derived: sum of 4 quarters · filed 2025-05-13 | |
| 2024-06-30 | 634.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | 634.00K shares 10-Q · filed 2024-08-13 | 634.00K shares derived: sum of 3 quarters · filed 2025-05-13 | 634.00K shares derived: sum of 4 quarters · filed 2025-05-13 | |
| 2024-03-31 | 0.00 shares 10-Q · filed 2025-05-13 | 0.00 shares derived: sum of 2 quarters · filed 2025-05-13 | 0.00 shares derived: sum of 3 quarters · filed 2025-05-13 | 52.00K shares derived: sum of 4 quarters · filed 2025-05-13 | |
| 2023-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | 0.00 shares derived: sum of 2 quarters · filed 2025-03-27 | 52.00K shares derived: sum of 3 quarters · filed 2025-03-27 | 158.67K shares 10-K · filed 2025-03-27 | 197.56K shares 10-K · filed 2024-04-16 |
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | 52.00K shares derived: sum of 2 quarters · filed 2024-11-13 | 158.67K shares 10-Q · filed 2024-11-13 | ||
| 2023-06-30 | 52.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | 158.67K shares 10-Q · filed 2024-08-13 | |||
| 2023-03-31 | 106.67K shares 10-Q · filed 2024-05-15 | ||||
| 2022-12-31 | 0.00 shares 10-K · filed 2024-04-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |